Sarina Piha-Paul - Dissemin

All papers authored by Sarina Piha-Paul

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2024 Roberto Carmagnani Pestana

, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha Paul

, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour and 19 other authors

Data from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Upload

Roberto Carmagnani Pestana

, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha Paul

, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour and 19 other authors

Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Upload

Roberto Carmagnani Pestana

, Justin T. Moyers, Jason Roszik, Shiraj Sen, David S. Hong, Aung Naing, Cynthia E. Herzog, Siqing Fu, Sarina A. Piha Paul

, Jordi Rodon, Timothy A. Yap, Daniel D. Karp, Apostolia M. Tsimberidou, Shubham Pant, Maria A. Zarzour and 19 other authors

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

, Apostolia M. Tsimberidou, Filip Janku, Jordi Rodon, Shubham Pant, Ecaterina E. Ileana Dumbrava, Siqing Fu, David S. Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song and 3 other authors

Representativeness of Study Participants from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

TABLE 1 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

TABLE 3 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

Supplementary Figure 1, Supplementary Table S1, and Supplementary Table S2. from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

FIGURE 1 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

This paper was not found in any repository, but could be made available legally by the author.

Vivek Subbiah

, Niamh Coleman

, Sarina A. Piha-Paul

, Apostolia M. Tsimberidou

, Filip Janku

, Jordi Rodon

, Shubham Pant

, Ecaterina E. Ileana Dumbrava

, Siqing Fu

, David S. Hong

, Shizhen Zhang

, Ming Sun

, Yunfang Jiang

, Jason Roszik

, Juhee Song

and 3 other authors

Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

FIGURE 3 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

FIGURE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

Vivek Subbiah, Niamh Coleman, Sarina A. Piha Paul

Data from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Upload

This paper is made freely available by the publisher.

Sarina A. Piha-Paul

, Binghe Xu

, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, David S. Hong, Jordi A. Rodon, Apostolia M. Tsimberidou, Kanwal Raghav, Jaffer A. Ajani

, Anthony P. Conley, Frank Mott, Ying Fan, Jean Fan and 10 other authors

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

Download from doi.org

2023 Timothy P. DiPeri

, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press

, Sarina A. Piha Paul

, Ecaterina E. Dumbrava, Funda Meric-Bernstam

Table S1 from Discordance of HER2 Expression and/or Amplification on Repeat Testing

Upload

Timothy P. DiPeri

, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press

, Sarina A. Piha Paul

, Ecaterina E. Dumbrava, Funda Meric-Bernstam

Table S2 from Discordance of HER2 Expression and/or Amplification on Repeat Testing

Upload

Timothy P. DiPeri

, Kathleen Kong, Kaushik Varadarajan, Daniel D. Karp, Jaffer A. Ajani, Shubham Pant, Michael F. Press

, Sarina A. Piha Paul

, Ecaterina E. Dumbrava, Funda Meric-Bernstam

Data from Discordance of HER2 Expression and/or Amplification on Repeat Testing

Upload

Jason J. Luke, Sarina A. Piha Paul

, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Janku

Supplementary Figure S5 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Upload

Jason J. Luke, Sarina A. Piha Paul

, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Janku

Supplementary Figure S7 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Upload

Jason J. Luke, Sarina A. Piha Paul

, Theresa Medina, Claire F. Verschraegen, Mary Varterasian, Aoife M. Brennan, Richard J. Riese, Anna Sokolovska, James Strauss, David L. Hava, Filip Janku

Supplementary Figure S6 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Sarina Piha-Paul